BIOCON GROUP

FACT SHEET

September-12

H1 FY 2013 vs. H1 FY 2012
Q2 FY 2013 vs. Q2 FY 2012

BIOCON LIMITED (CONSOLIDATED) UNAUDITED
PROFIT & LOSS STATEMENT (Rs. Crores)

Particulars	H1 FY 13	H1 FY 12	Variance
INCOME			
Biopharmaceuticals	734	640	15%
Branded formulations - India	178	122	45%
Total Biopharmaceuticals	912	762	20%
Contract research	252	180	40%
Total Sales	**1,164**	**942**	**24%**
Other income	71	59	20%
Total Revenue	1,235	1,001	23%
EXPENDITURE			
Material & Power Costs	570	449	27%
Staff costs	172	137	26%
Research & Development	79	51	54%
Depreciation & Amortisation	[illegible]	[illegible]	[illegible]
PBT	213	186	14%
Taxes	43	30	44%
NET PROFIT FOR THE PERIOD	170	156	9%
Minority Interest	1	-	-
NET PROFIT FOR THE PERIOD, AFTER MINORITY	169	156	8%
EPS Rs.	**8.5**	**7.8**	

Note: 1.The figures are rounded off to the nearest crores, percentages are based on absolute numbers

2. Figures of the Comparative period have been regrouped wherever necessary

Biopharmaceuticals Income Includes:			
Licensing development fees	-	*51*	
Licensing Income	*14*	-	

17/19

BIOCON LIMITED (CONSOLIDATED) UNAUDITED
BALANCE SHEET (Rs. Crores)

	September 30, 2012	March 31, 2012
EQUITY AND LIABILITIES		
Shareholder's Funds		
(a) Share capital	100	100
(b)Reserves and surplus	2,347	2,172
	2,447	**2,272**
Minority interest	**4**	**4**
Non-current liabilities		
(a) Long-term borrowings	125	70
(b)Deferred tax liability (net)	39	-
(c)Other long-term liabilities	450	583
(d) Long-term provisions	4	-
	618	**653**
Current liabilities		
(a)Short-term borrowings	129	187
(b)Trade payables	311	348
(c)Other current liabilities	364	269
(d)Short-term provisions	68	212
(b) Good will on consolidation	12	12
(c) Non-current investments	78	64
(d) Deferred tax asset (net)	-	8
(e) Long term loans and advances	206	185
(f) Other non-current assets	186	29
	2,165	**1,946**
Current assets		
(a) Current Investments	406	492
(b) Inventories	405	378
(c)Trade receivables	503	492
(d)Cash and cash equivalents	341	523
(e)Short term loans and advances	82	79
(f)Other current assets	39	35
	1,776	**1,999**
TOTAL	3,941	3,945

19/19